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1 Summary 
 
Background: Corneal infections are common and potentially devastating diseases in all 
species. As pathogen resistance against antibiotic treatment is a growing concern, alternative 
treatment methods are an important focus of research. Corneal crosslinking (CXL) is a very 
promising oxygen radical-mediated alternative to antibiotic treatment. The main goal of this 
study was to assess whether a difference in bactericidal efficacy on clinical bacterial isolates 
could be observed between the current standard and an accelerated treatment protocol 
delivering the same total energy dose (5.4 J/cm2). 
Methods: Cryopreserved isolates were thawed, cultured, brought into suspension and 
irradiated for 30 minutes at 3mW/cm2 (standard protocol) or 5 minutes at 18mW/cm2 
(accelerated protocol), respectively. After treatment, the bacterial suspensions were diluted 
and cultured overnight on agar plates. CFUs were then counted and statistically compared 
between groups using a linear mixed effects model.  
Results: Both CXL protocols demonstrated a significant bactericidal effect on all tested 
isolates when compared to untreated controls.  No difference between protocols was 
observed. 
Conclusion: The accelerated CXL protocol can be recommended for empiric use in the 
treatment of bacterial corneal infections in veterinary species while awaiting culture results. 
This will facilitate immediate treatment and minimize the required anesthetic time or even 
obviate the need for general anesthesia.  
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2 Zusammenfassung 
Allgemein: Infektionen der Kornea sind häufig auftretende und ernstzunehmende Probleme 
vieler Spezies. In Zeiten von steigenden Berichten über Antibiotikaresistenzen sollten 
vermehrt alternative Behandlungsmethoden in Betracht gezogen werden. Corneal 
Crosslinking (CXL) ist ein vielversprechendes Verfahren, das Mikroorganismen mittels 
Sauerstoffradikalen schädigt. Ziel dieser Studie war herauszufinden ob ein Unterschied 
besteht zwischen dem derzeitigen Standard- und einem beschleunigten Behandlungsprotokoll, 
welche die selbe Gesamt-Energiedosis (5.4 J/cm2) abgeben, bezüglich bakterizider Wirkung 
gegen klinische bakterielle Isolate. 
Methoden: Kryokonservierte Isolate wurden kultiviert, in Lösung gebracht und für 30 
Minuten bei 3mW/cm2 (Standard-Protokoll) beziehungsweise 5 Minuten bei 18mW/cm2 
(beschleunigtes Protokoll) bestrahlt. Nach der Behandlung wurden die Lösungen verdünnt 
und auf Agar-Platten kultiviert. Nach der Inkubation wurden CFU’s gezählt und die Gruppen 
mittels eines linear mixed effects Modell verglichen.  
Resultate: Beide CXL Protokolle zeigten einen signifikanten bakteriziden Effekt auf alle 
getesteten Isolate im Vergleich zu den unbehandelten Kontrollen. Es gab keinen Unterschied 
zwischen den zwei Protokollen selber. 
Schlussfolgerung: Das beschleunigte CXL Protokoll kann bei septischer Keratitis bei 
veterinärmedizinischen Patienten eingesetzt werden, ohne dass auf die Resultate der Kultur 
gewartet werden muss. Dies erleichtert eine sofortige Therapie und verkürzt die Dauer der 
Anästhesie.  
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3 Introduction 
 
3.1 Background 
Corneal ulcers and erosions are a common affliction in veterinary patients. Approximately 
20% (2194/12085) of all ophthalmic small animal patients and 30% (548/1858) of all 
ophthalmic equine patients seen in our clinic during the last 20 years presented with a corneal 
defect. These defects posed a threat to the integrity of the eye in 61% (1347/2194) and 70% 
(383/548) of these small animal and equine patients, respectively. The defects were perforated 
upon initial presentation or continued to progress to perforation in 21% (453/2194) and 14% 
(75/548) of the small animal and equine patients, respectively (Patient database 1995-2014, 
Section of Veterinary Ophthalmology, Vetsuisse Faculty, University of Zurich). 
Although the causes differ, all species can be affected by secondary bacterial infections once 
the epithelial barrier is damaged. The conjunctival sac microbiota normally prevents the 
overgrowth of potentially pathogenic agents (1). Opportunistic microorganisms can originate 
from this normal ocular flora, and take advantage of a weakened ocular surface defense 
system.  
Primary diseases of the ocular surface that weaken the cornea’s anatomic barriers and 
physiologic defenses (low corneal sensation, quantitative and qualitative tear film 
deficiencies, exposure keratitis, trauma, eyelid abnormalities) can directly cause 
collagenolysis, but also predispose the cornea to secondary infections (2, 3). As a result, 
brachycephalic breeds and patients with tear film deficiencies (4) are two common patient 
categories that are especially susceptible to melting keratitis. In dogs with 
Keratoconjunctivitis sicca (KCS, dry eye syndrome), the bacteria are not washed  from the 
cornea and conjunctiva effectively enough and therefore accumulate on these surfaces (4). 
Also, the normal tear film contains antibacterial peptides, proteinases and proteinase-
inhibitors in a well balanced relationship. When the tear film can not be evenly distributed or 
the components are misbalanced, a convenient port of entry for pathogens is created (3). 
Dogs, especially brachycephalic breeds, frequently present with bacterial infections of the 
cornea. Eyelid and eyelash abnormalities and tear film dysfunctions can have a great impact 
on the corneal integrity in dogs as well (2, 3). Trauma (e.g. through fights, scratch-injuries) 
and herpetic keratitis are common initiating events in cats (2, 5). Horse eyes are commonly 
affected by (micro)trauma and secondary fungal infections (2, 6, 7).  
Primary infections play a relatively minor role in corneal diseases, but should be mentioned 
nevertheless. Putative herpes virus infection is the most common primary corneal infection 
and occurs far more frequently in cats than in dogs or horses. Other reported pathogens are 
Canine Distemper Virus, Moraxella spp., and Mycoplasma spp. (2, 3, 8). Since Mycoplasma 
spp. require specialized growth media or additional diagnostic methods, they may go 
undetected (8, 9). 
Once present, an injury to the cornea can heal rather quickly (within hours to days), especially 
if the injury only affected the surface epithelium, or it can result in serious complications that 
might threaten eyesight or the globe itself (3). 
The majority of complications are caused by secondary bacterial infections. In the course of 
the inflammatory process the corneal stroma may begin to melt (keratomalacia). This is a 
result of activated enzymes such as collagenases, elastases, matrix-metalloproteinases 
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(MMPs) and cathepsins and an imbalance between these proteolytic enzymes and the 
proteinase inhibitors present in the cornea and precorneal tear film. Such a release of 
collagenases is most often caused by secondary bacterial or rarely fungal infections (10). The 
malacic process can lead to the corneal ulcer deepening,  descemetocele formation, and 
possibly progression to corneal perforation (2, 3, 11). 
 
3.2 Dogs 
Research on the resident microflora showed positive isolation rates of 46% to 91% in 
clinically healthy dogs and isolation rates of 66.2% (12) and 53% (8) in dogs with external 
ocular disease (conjunctivitis, traumatic laceration, blepharitis, dacryocystitis, and corneal 
ulceration). Variations in the type and frequency of isolates may be a result of geography, 
culturing technique, breed and season (11).  
Previous studies concluded that gram-positive bacteria predominate the normal canine ocular 
microflora, with Staphylococcus (S.) epidermidis, S. aureus, Streptococcus spp., Neisseria 
spp., Enterobacteriaceae, and Pseudomonas spp. as most prevalent isolates (1, 9, 11). 
In an investigation in Beijing, China, Staphylococcus spp. were the most frequently isolated 
bacteria from 29 eyes with ulcerative keratitis. Streptococcus spp. and Pseudomonas spp. 
were second, and third, respectively (13). Gram-positive bacteria predominated over gram-
negative in the conjunctival sac of clinically normal dogs and dogs with ulcerative keratitis in 
Ceará, Brazil, and Staphylococcus spp. was the most frequently isolated genus (1, 14). 
 
3.3 Cats 
Besides primary pathogens such as Feline Herpes Virus 1 (FHV1), cats are also at risk for 
trauma, and secondary bacterial infections (2, 11). 
In Taiwan, 51% Staphylococcus spp. (S. aureus (43.3%), S. epidermidis (30%), S. warneri 
(26.6%)), 13.5% Pseudomonas (P.) aeruginosa, 10% Pasteurella multocida and 8% beta-
haemolytic Streptococcus spp. were isolated from cats with ulcerative keratitis. (15). The 
following rates have been reported for healthy cats: Staphylococcus spp. 27%, 
Corynebacterium spp. 1.3-5%, Bacillus spp. 3-5%, Streptococcus spp. 2-2.5% and 
Mycoplasma spp. 0-5% from the conjunctiva and Staphylococcus spp. 23-28%, Streptococcus 
spp. 0-2%, Bacillus spp. 2-5% and Corynebacterium spp. 1.6% from the eyelids (16, 17). 
Overall, the cat has a lower presence of bacteria on the normal ocular surfaces compared to 
the dog (11, 16, 18). 
 
3.4 Horses 
Horses might be more prone to ocular trauma due to their large globe and exposed position of 
the cornea (7). It has also been reported that thoroughbred race horses commonly suffer 
corneal injury due to track surface material being kicked up by other horses during a race (19). 
In one study the most frequently occuring bacterial isolate was P.  aeruginosa (22%), 
followed by Streptococcus equi ssp. zooepidemicus (13%) and S. aureus (6%) (20). Another 
study also found S.epidermidis and S. xylosus at 6.8% each (19). 
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3.5 Diagnostics The	clinical	 evaluation	of	 a	potential	ocular	 surface	 infection	 includes	 several	diagnostic	 tests.	First,	a	thorough	examination	includes slit lamp biomicroscopy of eyelid, third eyelid, corneal 
and conjunctival anatomy and function. A Schirmer tear test on both eyes was used to exclude 
KCS as a primary cause of the corneal condition. Fluorescein staining combined with a 
slitlamp biomicroscopy examination was performed to evaluate the extent and depth of a 
corneal defect. Bacterial and fungal sampling with sterile swabs and subsequent culture and 
sensitivity testing, and cytology were performed to evaluate the degree of inflammation and to 
identify potential causal microorganisms (2, 10). 	
3.6 Conventional therapy 
Initial therapy of any case of septic corneal disease, besides identification and removal or 
correction of the cause, consists of topical antimicrobial therapy, a mydriatic agent and in 
small animals, placement of an e-collar to prevent further damage (2). Anticollagenase 
treatment can be added, depending on the presence of a stromal defect/melting process and/or 
the presence and density of a neutrophil infiltrate (2, 21, 22). 
Studies have shown that corneal ulcers may heal faster and with fewer complications if 
anticollagenases are utilized (2, 21, 22).  They help to prevent enzymatic degradation of 
stromal collagen and consequently reduce the progression of stromal melting, increase 
epithelial healing and minimize corneal scarring (2, 21, 22). Effective examples of proteinase 
inhibitors used in veterinary ophthalmology, among others, are disodium ethylene-
diaminetetra-acetic acid (EDTA) and autologous serum (2, 21, 22).  
An empiric antimicrobial choice for prophylaxis or treatment of ocular surface infections is a 
combination ophthalmic ointment referred to as „triple antibiotic“, which contains neomycin, 
polymyxin B and bacitracin (4, 23, 24). This combination provides broad-spectrum 
antimicrobial activity (25). While these drugs are not lipid-soluble, they penetrate into the 
stroma when the corneal epithelium is disrupted (25). Neomycin shows good activity against 
Staphylococcus spp. and some gram-negative bacteria, polymyxin B covers P. aeruginosa as 
well as E. coli, and bacitracin is active against gram-positives, similar to beta-lactam 
antibiotics (26). In ophthalmic solutions, bacitracin was replaced with gramicidin, another 
polypeptide antibiotic, due to its transcorneal penetration capability. Gramicidin has the same 
qualities as bacitracin; it is active against gram-positive bacteria and should not be 
administered systemically due to toxicities (3). 
Other topically applied antibiotics used for corneal diseases in veterinary ophthalmology, 
especially after antimicrobial sensitivity testing, are gentamicin, chloramphenicol, tetracycline 
(oxytetracycline), erythromycin, tobramycin, and in severe cases where potentially resistant 
pathogens are involved, fluoroquinolones such as, ciprofloxacin, ofloxacin, and moxifloxacin 
(4, 24-27). 
 
3.6.1 Antimicrobial resistance 
As stated in our study from 2017 (23), Streptococcus and Staphylococcus spp. demonstrated 
an increased resistance against fluoroquinolones compared to previous reports. Over 50% of 
Streptococcus isolates were intermediately susceptible and a significant number of isolates 
were resistant to the second generation fluoroquinolones, enrofloxacin and norfloxacin. 
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Almost 50% (15/31) of canine Staphylococcus isolates was also resistant to these 
fluoroquinolones. In 2006 ,Tolar et al. (4) found 100% of Streptococci and Staphylococci to 
be susceptible to enrofloxacin. However, resistance might have been underestimated in this 
study, since intermediate results were pooled with susceptible results. Various reports in both 
human (28-32) and veterinary medicine (24), including the present study (23), clearly suggest 
increased fluoroquinolone resistance. Ofloxacin (2nd generation), ciprofloxacin (2nd 
generation) and moxifloxacin (4th generation), are commonly used fluoroquinolones in 
veterinary ophthalmology. Because Staphylococci and Streptococci accounted for >66% of 
bacterial isolates, and >50% of those were intermediately susceptible or resistant to second 
generation fluoroquinolones, the routine first choice use of these antibiotics in corneal ulcer 
patients cannot be currently recommended. Bacterial resistance against 3rd and 4th generation 
fluoroquinolones is still relatively rare but can logically be expected to increase as has 
occurred for the 1st and 2nd generation fluoroquinolones (28, 32, 33). Gentamicin is typically 
used against Gram-negative pathogens, with special efficacy against P. aeruginosa (34), 
which is supported by the results of this study. The reported susceptibility of Gram-positive 
bacteria for gentamicin is variable. Gentamicin resistance was observed in 95-100% of tested 
Streptococcus isolates in our study (4, 12, 19, 20, 23, 34, 35). Cephalosporins have typically 
been effective against Streptococcus and Staphylococcus spp. Whereas cephalosporin 
resistance was not observed in Streptococcus spp. a cephalosporin resistance in approximately 
20% of the tested Staphylococcus isolates from dogs was demonstrated (23). Varges et al. 
(24) reached similar conclusions, suggesting that cephalosporin resistance in Staphylococcus 
spp. might be an emerging problem. (36) 
The same concern applies to the traditionally anti-staphylococcal antibiotic fusidic acid (37) 
to which a significant proportion of all tested Staphylococci in this study were resistant (23).  
The intrinsic resistance of Staphylococcus and Streptococcus spp. to polymyxin B and of 
Streptococcus spp. to neomycin was confirmed with 100% of isolates being resistant in this 
study (23). Effectivity against Staphylococcus isolates was variable for neomycin. Resistance 
to neomycin and polymyxin B was observed in 16% of canine P. aeruginosa isolates (23). 
These results support the variable neomycin resistance in Staphylococcus spp. and 
Pseudomonas spp. strains previosly reported (4, 12). Pseudomonas isolates are routinely 
susceptible to polymyxin B, and acquired resistance is reportedly rare (38). Bacitracin is 
effective against Gram-positive bacteria, but ineffective against Gram-negative organisms, 
and P. aeruginosa is intrinsically resistant to bacitracin (39).  
 
3.6.2 Surgical therapy 
Surgical stabilization of the cornea is indicated in cases where the ulcer deepens despite 
ongoing medical therapy or where the integrity of the globe is already significantly 
compromised upon initial presentation (3, 40). Methods for surgical treatment of septic ulcers 
include conjunctival grafts and flaps, amniotic membrane grafting, corneoscleral and 
corneoconjunctival transposition, autogenous corneal grafting and corneal transplantation (3, 
7). Unfortunately, surgical interventions may significantly increase scar formation and lead to 
vision impairment; which can be quite severe, depending on ulcer size, localisation and 
surgical method applied (3, 7, 41, 42). 
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3.7 Alternative or adjunctive treatment 
An alternative or adjunctive treatment method has been proposed in the form of the so-called 
corneal crosslinking (CXL) procedure (43, 44). Utilizing UV-A light and riboflavin, CXL is a 
procedure that was developed for the treatment of keratoconus in humans, in which it arrests 
progressive loss of structural integrity of the corneal stroma (44, 45). Natural enzymatic 
cross-linking is part of the post-translational modification of collagen, which increases the 
biomechanical stability of the cornea and raises the resistance to enzymatic digestion (44, 45). 
Riboflavin (Vitamin B2) acts as a photosensitizer when exposed to UV-A light with a 
wavelength at one of its absorption peaks (370nm), which results in the generation of free 
radicals (46-50). This process leads to free radical-induced elimination of microorganisms and 
apoptosis of cells and thus reduced inflammatory response in the irradiated area (46-48, 51). 
Additionally, riboflavin diffuses through cellular membranes and intercalates with 
microorganismal nucleic acids, inducing oxidative genomic damage (49, 50, 52-54). Finally, 
CXL leads to free radical-induced photochemical crosslinking and the formation of chemical 
bridges between protein residues and/or other molecules (45, 55-57). Possible indications for 
CXL treatment in human medicine are keratoconus (44), post LASIK keratectasia (58-60) and 
corneal edema and bullous keratopathy (61-65). The indications for the use of CXL have 
recently been expanded to include treatment for septic keratitis (45, 47, 66-76). 
Efficacy has been established for photoactivated riboflavin treatment of infectious keratitis in 
veterinary and human patients (40, 77-84) in a procedure called photoactivated chromophore 
for infectious keratitis-corneal crosslinking (PACK-CXL). However, variability in efficacy 
between individual patients exists, especially in horses (81, 85). All authors concluded that 
PACK-CXL represents a very promising treatment method for infectious melting keratitis, but 
further investigation is required in order to optimize the energy delivery protocol in veterinary 
medicine (79-81, 84). Corneal crosslinking used for the specific clinical indication of 
infectious keratitis will be identified as PACK-CXL throughout the rest of this thesis. All 
other uses of corneal crosslinking will be identified using the general abbreviation CXL 
throughout the rest of this thesis.  
PACK-CXL has a variable inhibitory effect on microorganisms in vitro, depending on the 
type of microorganism and pretreatment (47, 73-75). A consistent bactericidal effect has been 
demonstrated (40, 47, 73, 74, 86, 87) using standardised, non-ocular strains or single strains 
obtained from human patients (47, 73, 74). However, genetic variability between strains and 
isolates could affect their susceptibility to external physical and chemical stimuli (88, 89), 
which could explain the variability in clinical efficacy. The standard CXL protocol, developed 
for keratoconus therapy in human patients, was first described by Wollensak and colleagues 
and is often referred to as the ‘Dresden protocol’ (44). This protocol involves 30 minutes of 
saturation with riboflavin and 30 minutes of UV-A irradiation (28). 
Accelerated CXL protocols were developed to decrease treatment duration. According to the 
Bunsen–Roscoe photochemical law of reciprocity, the effects of any photochemical reaction 
(in the current context, the PACK-CXL procedure) can be maintained as long as the total 
energy delivery is also maintained by adapting the radiation intensity delivered per unit of 
time (fluence) (90). This implies that the total energy delivered (5.4 J/cm2) and the effect of 
CXL treatment should be similar for an irradiation of 3 mW/cm2 for 30 min, and one of 18 
mW/cm2 for 5 min. (90). 
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However, the biomechanical stiffening effect is oxygen dependent and decreases with 
treatment duration shortening and intensity increase (91, 92). The antimicrobial effect of 
PACK-CXL on the other hand is oxygen-independent and not affected by shortening of the 
PACK-CXL procedure (75). This would shorten the duration of, or obviate the need for 
general anesthesia in veterinary patients. 
 
3.8. Hypotheses and aims 
 
Hypotheses:  
The following hypotheses will be tested: 
 
1. All bacterial isolates of veterinary relevance tested are susceptible to PACK-CXL. 
 
2. The bactericidal effect of accelerated PACK-CXL (5 min at 18mW/cm2) is at least equal to 
that of the standard protocol (30 min at 3 mW/cm2). 
 
Specific aims:  
 
1. Within the scope of the Masters thesis that was performed on the topic, the prevalence of 
bacterial isolates from corneal ulcers obtained from dogs and cats between 2003 and 2013 
was analysed. The most common and pathologically relevant isolates were identified: 
Staphylococcus pseudintermedius, Staphylococcus aureus, beta-hemolytic streptococci and 
Pseudomonas aeruginosa. This panel of pathogens will be used as sample specimens to test 
the bactericidal efficacy of PACK-CXL (see hypothesis 1). 
 
2. Two PACK-CXL duration and intensity settings will be compared: standard protocol 
PACK-CXL (30 min at 3mW/cm2) and accelerated PACK-CXL (5 min at 18mW/cm2)(see 
hypothesis 2). 
 
4 Materials and Methods 
4.1 Preliminary trials 
The basic study design idea consisted of adding a bacterial solution (with a known bacterial 
concentration) to corneal tissue placed in a well of a well plate, which would then be 
illuminated at a specific irradiance (47, 73-75, 93-96). By doing this we attempted to achieve 
conditions that were as close to the in vivo situation as possible. After treatment, we would 
retrieve the bacteria and count colony forming units (CFU’s), comparing them to CFU’s 
obtained from an untreated control sample (74, 75, 93, 96). In order to make the study design 
repeatable and to eliminate all factors that might contribute to false results, a few technical 
details were evaluated in preliminary trials. 
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4.1.1 Temperature and evaporation 
Temperature measurements were conducted due to our concern of inducing a significant 
temperature increase in small amounts of irradiated medium, which would potentially lead to 
bacterial growth arrest and evaporation losses.  
No temperature change occured as measured with an IR thermometer (IR Thermometer Dual 
Laser EXTECH INSTR. 42509, FLIR Commercial Sysems Incorporated, Nashua, USA) 
during the 30-minute irradiation of 30μl 0.9% Natrium Chloride solution (B. Braun Medical 
AG, Sempach, Switzerland) with 3mW/cm2 irradiance (focal distance of approximately 5 
cm). Virtually no fluid evaporation was detected during a 30 minute irradiation with 
3mW/cm2 irradiance as measured via fluid repipetting post CXL treatment. 
 
4.1.2 Corneal tissue 
Porcine corneal tissues were used in ten earlier trials following a modified experimental 
protocol. Freshly enucleated nonbrewed porcine eyes were obtained at a local slaughterhouse 
(Schlachthof Zürich, Veterinärdienst Stadt Zürich, Herdernstrasse 63, 8004 Zürich). The 
epithelium was bluntly removed with scalpel blades (Swann Morton® 10&15, Swann-Morton 
Limited, Sheffield, UK) and the cornea with a scleral margin was isolated. The corneas were 
placed on a microkeratome (SCHWIND Carriazo Pendular, Schwind eye-tech-solutions, 
Kleinostheim, Deutschland) and lamellae of 130μm thickness and 10 mm diameter were cut 
(75). To avoid contamination an antisepsis-protocol was tested. The corneal lamellae were 
placed into a 1:50 Betadine (Betadine Lösung standartisiert, Mundipharma Medical 
Company, Hamilton/Bermuda, Zweigniederlassung Basel) : 0.9%-NaCl solution for 1 minute, 
then dipped in sterile 0.9% NaCl and placed in another vessel with sterile 0.9% NaCl for 
transport to the bacteriology lab. 
 
4.1.3 Treatment groups 
ATCC strains of P. aeruginosa (ATCC 27853), S. pseudintermedius (ATCC 21284) and 
Streptococcus canis (isolate from veterinary patient with septic keratitis) were chosen for 
these pilot experiments. Working solutions held a bacterial concentration of 4.5x104/30µl. 
In the corneal lamella pre-trials the riboflavin/ultraviolet-light (Ri/UV) treatment group was 
compared to three control groups: a no treatment control group (C) – a control group that was 
UV-A treated only, without the presence of riboflavin in the bacterial suspension (UV) – and 
a control group that had riboflavin present in the bacterial suspension but was not UV-A 
treated (Ri). 
Treatment group in pre-trials: 
• Ri + UV-A 
Control groups in pre-trials:  
• No treatment (C) 
• UV-A only 
• Ri only 	
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4.1.4 Retrieval of bacterial isolates for quantitative culture 
For the experiments, the individual lamellae were placed into single wells of a 48-well cell 
culture plate (Falcon® Multiwell 48 well, Corning Incorporated, Corning, USA) and then 
covered with either 30μl 0.1% riboflavin containing bacterial suspension (Ri and Ri/UV) or 
30μl 0.9%-NaCl containing bacterial suspension (C and UV). After irradiation of the Ri/UV 
and UV samples, the 30μl of bacterial suspension were retrieved for all four experimental 
groups separately, and diluted in the same way as in the main experiments. The corneal 
lamellae were discarded after suspension retrieval.  
Preliminary experiments were performed to determine how to retrieve the bacteria remaining 
on the lamellae: In two trials, lamellae were pressed onto an agar plate. Since no dilution was 
possible for this procedure, the contact areas only showed bacterial overgrowth and 
quantification was not possible. Also, due to the non-rigid nature of the humid lamellae, it 
was not possible to perform the direct contact printing in a standardised manner.  
Another trial involved rinsing solutions. The lamellae were placed in a 0.9% NaCl solution 
and shaken on a plate shaker at 500 rpm for 30 minutes. Afterwards, the solutions were 
diluted and cultivated on agar plates in the same way as in the main experiments. The results 
were comparable to those of the primary solution (that was retrieved after irradiation). A third 
method that was discussed was homogenisation of the lamellae, followed by the same 
methods (dilution and cultivation on agar with CFU counting). This approach was not pursued 
further due to ambiguity about how to homogenize the lamellae, and whether this approach 
itself would affect bacterial growth.  
 
4.1.5 Conclusions 
The trial using porcine lamellae was performed 5 times with S. pseudintermedius (ATCC 
21284), 3 times with P. aeruginosa (ATCC 27853) and twice with Streptococcus canis. The 
results were inconsistent, even between repeats on the same bacterial strain with the same 
methods: In some cases less growth was observed in the control group (C) than in the treated 
group (Ri/UV). These results imply that the presence of the corneal tissue was somehow 
responsible for the large variation between measurements. This assumption was confirmed by  
obtaining consistently repeatable measurements within bacterial strains using the final 
experimental protocol outlined in the main study (see Results). 
The ‘corneal lamella’ protocol did not demonstrate any benefits compared to the final 
experimental protocol used in the main study and was discarded due to its needlessly 
complicated and time-consuming design as well as the poorly reproducible outcome.  
Since no differences in bacterial survival were observed between the three control groups (C, 
UV-A only and Ri only), the UV-A only (UV), and the riboflavin only (Ri) controls were 
omitted in the main experiments. 
4.2 Bacterial isolates: 
During a period of two years (2013-2014), 30 bacterial isolates from veterinary patients with 
septic keratitis that were presented to the University of Zurich Veterinary Medical Teaching 
Hospital were collected and cryopreserved at -80°C at the Institute for Veterinary 
Bacteriology (IVB), Vetsuisse Faculty, University of Zurich. In	accordance	with	the	IVB	and	the	Section	for	Epidemiology	18	of	the	collected	wild	type	isolates	were	selected	to	participate	in	
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the	study:	dogs (11), horses (5), and cat and guinea pig (1 each) (Table 1). Inclusion	criteria	were	 that	 the	 isolate	 had	 to	 originate	 from	 a	 septic	 corneal	 defect/ulcer	 from	 a	 companion	animal	 (incl.	 horses)	 patient	 at	 our	 clinic	 and	 had	 to	 belong	 to	 either	 one	 of	 the	 genera	Staphylococcus,	 Streptococcus,	 Pseudomonas	 or	 Pasteurella,	 since	 those	 were	 the most 
commonly isolated bacterial pathogens from cats, dogs and horses with septic keratitis that 
were presented to the University of Zurich Veterinary Medical Teaching Hospital as 
evaluated in a previous study (23). This	explains	the	unbalanced	number	of	isolates	per	patient	species	and	bacterial	species. The goal was to select isolates that are frequently responsible for 
septic processes in the cornea of companion animals. More seldomly seen pathogens like 
Acinetobacter spp., Moraxella spp. or Serratia spp. were excluded as well as Mycoplasma 
spp., Chlamydophila spp. and Leptospira spp. Fresh subcultures (see below) of these frozen 
isolates were prepared on Columbia Sheep Blood plates (Oxoid, Pratteln, Switzerland). 
The spectrum of isolates consisted of the following species:  
- Staphylococcus spp.: 8 isolates 
- Streptococcus spp.: 5 isolates  
- Pasteurella spp.: 3 isolates	
- P. aeruginosa.: 2 isolates 
 
Table 1: List of the isolates used in this study	
Isolate genus Case Number Isolate species Sampled species 
Staphylococcus 14-1547 SK1 Staphylococcus aureus Horse 
 15-1745 SK1 Staphylococcus aureus Horse 
 14-1774 SK2 Staphylococcus epidermidis Dog 
 15-395  Staphylococcus epidermidis Dog 
 15-1852 SK1 Staphylococcus epidermidis Guinea Pig 
 15-1913 SK5 Staphylococcus pseudintermedius Dog 
 15-1125 SK1 Staphylococcus haemolyticus Dog 
 15-1305 SK2 Staphylococcus lentus Horse 
Streptococcus 15-799 SK1 Streptococcus canis Dog 
 15-1371 SK1 Streptococcus canis Dog 
 15-1913 SK4 Streptococcus canis Dog 
 15-1305 SK1 Streptococcus equi ssp. zooepidemicus Horse 
 14-1547 SK1 Streptococcus dysgalactiae ssp. equisimilis Horse 
Pseudomonas 15-1308 SK1 Pseudomonas aeruginosa Dog 
 15-1670 SK1 Pseudomonas aeruginosa Dog 
Pasteurella 15-1353 SK1 Pasteurella multocida Cat 
 15-1371 SK3 Pasteurella canis Dog 
 16-110 SK1 Pasteurella dagmatis Dog 
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4.3 Bacterial suspension 
Each isolate (Table 1) was streaked onto a new Columbia Sheep Blood agar plate (Oxoid, 
Pratteln, Switzerland) and incubated over 20-24 hours at +37°C to obtain a uniform 
population with balanced growth. A 0.5 McFarland suspension was then prepared from these 
subcultures. The bacterial concentration of this suspension amounted to 1.5x105/μl. Three μl 
of this suspension were diluted 1:10 with 0.1% riboflavin solution (treated group (Ri/UV)) 
resulting in a suspension with a bacterial concentration of 4.5x104/30µl, which was used as 
starting suspension for further serial dilutions.  
 
4.4 Riboflavin solution 
A riboflavin concentration of 0.1% was used in all experiments. This concentration was 
achieved by diluting 2ml riboflavin (Vitamin B2 Streuli, Uznach, Switzerland) with 8ml 0.9% 
NaCl (B. Braun Medical AG, Sempach, Switzerland).  
 
4.4 Experimental design  (See also Figure 1). 
30μl from the control (C) and the therapy samples (Ri/UV) were each pipetted into a single 
well of a 48-well-plate (Falcon® Multiwell 48 well, Corning Incorporated, Corning, USA). 
The well plate was shaken for 1 minute at 500 rpm and then wrapped in aluminum foil 
(Figure 2), leaving a window above the therapy sample (Ri/UV) in order to protect the control 
sample from irradiation. The wrapped plate was placed underneath the CXL-lamp at a 
distance where the UV-light-meter measured 3mW/cm2 and 18mW/cm2, respectively (focal 
distance of approximately 5 cm).(Figure 3) 
Standard protocol (3mW/cm2 for 30 minutes): the well Ri/UV was irradiated for 15 
minutes with a UV-A device (UV-Xtm illumination system (version 1000), IROC, 
Switzerland) at 3mW/cm2. The plate was then placed on a plate shaker for one minute 
at 500 rpm and irradiated again for another 15 minutes. After irradiation, the plate was 
placed on the plate shaker for another minute. 
Accelerated protocol (18mW/cm2 for 5 minutes): the well Ri/UV was irradiated for 5 
minutes with a UV-A device (CCL-VARIO Cross-linking system, Peschke Trade, 
Switzerland) at 18mW/cm2. After irradiation, the plate was placed on the plate shaker 
for one minute at 500 rpm. 
After each irradiation treatment, the 30μl of irradiated Ri/UV and non-irradiated control 
sample solution were retrieved from the well, pipetted into separate Eppendorf tubes and 
diluted 1:10 with 0.9% NaCl, followed by a serial dilution of both suspensions. Certain 
isolates required a dilution up to 10-5 whereas in others a dilution of 10-4 was sufficient. 
From the two highest dilutions, 100μl each were plated onto a Columbia Sheep Blood agar 
plate (Oxoid, Pratteln, Switzerland). This procedure was performed in duplicate. After 20-24 
hours of incubation at +37°C, colonies that had grown over night were counted on every plate 
(Figure 4). 
The experiment was conducted twice on different days with each isolate and each protocol. 
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Sample groups:  
• Ri/UV (standard) sample treated with Riboflavin and 30 min UV-A  
Irradiation at 3mW/cm2 
• C (standard)  untreated control (in NaCl) 
• Ri/UV (accelerated) sample treated with Riboflavin and 5 min UV-A  
Irradiation at 18mW/cm2 
• C (accelerated)  untreated control (in NaCl) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
•  Mixing of 3μl McFarland suspension with 27μl 0.1% Riboflavin solution (or 
0.9% NaCl for the controls (C))
2 •  30 minutes residence time.
3 •  Repeat mixing of the bacterial suspensions
4
•  Transfer of the suspensions to a well of a 48-well-plate, and then shaking on a 
plate shaker for 1 minute
5
• Wrapping the plate with aluminium foil leaving a window where the well with 
the Ri/UV sample can be irradiated
6
•  Depending on treatment protocol; irradiation of the Ri/UV sample at 18mW/
cm2 for 5 minutes (accelerated) or at 3mW/cm2 for 30 minutes (standard). For 
the 30 minute protocol, a break was made after 15 minutes where the plate was 
placed on the plate shaker again for one minute 
7
•  Pipetting both the irradiated Ri/UV and the non-irradiated control (C) samples 
out of the well plate into Eppendorf tubes containing 270μl NaCl 
8 •  10-fold serial dilution of both (Ri/UV and C) samples up to 10
-5
9 
•  Mixing 100μl of the two highest dilutions (103 and 104 or 104 and 105) by 
pipetting up and down and then streaking onto two blood agar plates.
10 •  Incubation of the agar plates at +37°C for 20-24 hours.
11 •  CFU counting on each plate. The mean value was noted.
Figure 1: Test procedure 
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4.6 Statistics 
Mean values for all (duplicate) plates were calculated as well as the bacterial count for all of 
these values (Figure 5). These numbers (Tables in annex) were compared to the initial count 
(0.5 McFarland = 4.5x104/30µl) in order to determine the bactericidal effect (reduction in 
bacterial concentration).  
Figure 3: UV-A irradiation with CXL-lamp. Figure 2: Well plate wrapped in 
aluminum foil. 
Figure 4: Representative example of agar plates after overnight incubation. 
Note the difference in number of bacterial colonies between the CXL treated 
(left: Ri/UV) and control (right: C) samples. Pasteurella multocida isolate. 
30 minute UV-A irradiation at 3mW/cm2. 	
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A linear mixed effects model was used to assess whether the combination riboflavin and UV-
A (Ri/UV) and the short vs. long protocol were significantly associated with a bactericidal 
effect. To adjust for clustering, the isolate was considered as a random effect in the linear 
mixed effects model. P < 0.05 was considered as statistically significant.  
The statistics program R 3.1.2., and the package nmle (97) were used for all statistical 
calculations (98)  
 
 
 
 
 
 		
5 Results 
Bacterial concentrations are presented in the box plot diagram below (Figure 6). A significant 
difference in bacterial concentration was observed between the control groups and the CXL 
treated groups, in which the number of microorganisms was reduced by approximately 50% 
compared to the control groups (p < 0.0001). No evidence for a significant difference in 
bacterial concentration was observed between the standard 30-minute 3mW/cm2 and the 
accelerated 5-minute 18mW/cm2 treatment protocols (p = 0.6). (Table 2). 
 																	
Figure 5: weighted average mean of colony 
numbers. Σc = sum of colonies of all plates, 
n1 = number of plates with the lowest 
evaluable dilution stage, n2 = number of 
plates with the next higher evaluable dilution 
stage, d = factor of the lowest evaluable 
dilution stage 
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 Lower CI 95% Bacterial 
concentration 
Upper CI 95% p-value 
Control 11856.446 14392.209 16927.973 <0.0001 
Treated group 
(Ri/UV) 
5918.466 8479.808 11041.149 <0.0001 
Concentration 
difference 
between 
protocols 
-1592.615 573.415 2739.444 0.6013 
	
Table 2: Effect sizes; results of the linear mixed effect model 
Figure 6: Box plot diagram. Comparison of two treatment protocols 
vs. Individual controls. 
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6 Discussion 
A variety of studies have demonstrated that PACK-CXL is a potentially valuable adjunctive 
or alternative therapy for the treatment of septic keratitis in both human and veterinary 
medicine (40, 78-84). The bactericidal effect of both standard 30-minute, and accelerated 
PACK-CXL protocols against sequenced reference strains has previously been established 
(75). Our study confirms these findings in non-sequenced „wild type“ isolates previously 
isolated from patients affected with septic keratitis in our clinic. All pathogens demonstrated 
equal susceptibility to both the standard and accelerated PACK-CXL protocols. 
Not every bacterial species demonstrated identical susceptibility to PACK-CXL. Some 
isolates seemed more susceptible than others. However, a statistical difference between 
species could not be proven due to a lack of individual test runs (number of repeats) for each 
species. A higher number of test runs for every single strain in a balanced number of strains of 
each species must be performed before definitive conclusions about differences in sensitivity 
to PACK-CXL between bacterial species can be made. Richoz et al. 2014 (75) tested both 
standard 30-minute and accelerated PACK-CXL protocols on the two sequenced reference 
strains S. aureus SA564 and P. aeruginosa PA01 from human patients, and received similar 
killing rates for both isolates. Martins et al. (47) found CXL to be more effective against S. 
epidermidis and S. aureus than against P. aeruginosa. A heterogenous response between 
Staphylococcus spp. and Pseudomonas spp. was also reported by Makdoumi et al. (74). They 
suggested the following factors to have an influence on these results: Oxidative stress might 
have an influence on cell wall structure, intracellular transport systems and metabolic 
pathways, and the possibility for exposure during cell division might be increased with a 
shorter length of cell cycle (leading to a higher risk for errors in genetic material followed by 
mutations or cell death). On this account, Schrier et al. (73) proposed that CXL protocols 
could be tailored by using different lengths of exposure time and different excitation 
wavelenghts depending on the target organism. Importantly, according to Makdoumi et al. 
(96) antibiotic resistant strains were just as susceptible to PACK-CXL treatment when 
compared to non-resistant strains. 
Various experimental designs were used in previous studies and include agar plates (47, 73), 
solutions in test tube corks (74), hand-cut porcine lamellae incubated with bacterial 
suspensions (75) and microscope slides with wells filled with a certain volume of fluid (96). 
In the present study, we decided on a bacterial suspension in 48 well plates because the 
diameter of each well (10mm) corresponds to the diameter of the irradiation beam (11mm). 
The amount of irradiated fluid was set to 30μl because this constitutes a sufficiently large 
volume to be handled without major pipetting losses, yet a sufficiently small volume to create 
a maximum layer thickness of approximately 300μm, which would most likely allow 
sufficient UV-A energy delivery throughout the entire fluid volume. In a pre-trial experiment 
we used a setting with porcine lamellae cut by a microkeratome, to ensure a defined thickness 
of the corneal tissue and thus optimal reproducibility. The lamellae were placed onto a cell 
culture plate and barely covered with a 30μl 0.1% riboflavin bacterial suspension in saline. 
This setup represented circumstances that were intended to be as close to real life as possible. 
For the final evaluations, the experimental protocol did not include the use of corneal 
lamellae, since no obvious differences in results were observed between protocols. Also, the 
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procedure involving corneal lamellae required much more preparation time and yielded 
results that were more difficult to reproduce.  
One significant weakness of the present study could be the experimental setup. It is unclear to 
which depths CXL-irradiation effectivity is reached in different substrates (85, 96). Therefore, 
we can not conclude that the applied fluid layer thickness is appropriate for this experimental 
design.  
The general application of PACK-CXL in veterinary medicine could mean an immense gain 
in the therapy of septic keratitis. A vast number of patients could be treated with less effort 
and financial investment, considering the complexity and high costs of a conventional 
conservative therapy. Shortening of the PACK-CXL treatment time would allow shorter 
anesthesia, and therefore reduce patient stress. 
PACK-CXL shows great promise for the reduction of antibiotic administration in animals 
with septic keratitis. Also, due to the low asset costs of the equipment and the relatively 
simple application of the procedure, PACK-CXL could become a widely used treatment 
option for septic keratitis in private veterinary practice. 
 	
7 Acknowledgements 
I would like to express my gratitude to the following contributors of this thesis: 
 
Simon Pot: for his constant support and many ideas that contributed to the completion 
of this thesis. 
 
Sarah Schmitt: for guidance and support in the laboratory, as well as constant backup 
and motivation. 
 
Sabine Kling: for her technical expertise and time. 
 
Sonja Hartnack: for her help and valuable inputs concerning the statistical part of the 
thesis. 
 
Richard McMullen: for proofreading, revising, providing constructive criticism and 
therefore raising the scientific quality of this manuscript 
 
Ella Hübschke: for helping me with lab work and teaching me manual skills.  
 
Silvia Stadler, Radka Andrysikova, Christina Casola, Deborah Brütsch and 
Katrin Voelter as my care team for their constant moral support and crisis 
management. 
 
Stiftung für Kleintiere and Schweizerische Vereinigung für Kleintiermedizin for  
financial support. 
 
	 20	
Special thanks also go to my family and friends who supported me in many ways 
throughout this time. 		
 
8 References 
 
1. Prado MR, Rocha MF, Brito EH, et al. Survey of bacterial microorganisms in the conjunctival 
sac of clinically normal dogs and dogs with ulcerative keratitis in Fortaleza, Ceara, Brazil. Vet 
Ophthalmol. 2005; 8(1): 33-37. 
2. Maggs DJ. Cornea and Sclera. In: Maggs DJ, Miller PE, Ofri R, Slatter DH, editors. Slatter's 
fundamentals of veterinary ophthalmology. 5th ed. St. Louis, Mo.: Elsevier; 2013. 184-219. 
3. Ledbetter EC, Gilger BC. Diseases and Surgery of the Canine Cornea and Sclera. In: Gelatt 
KN, Gilger BC, Kern TJ, editors. Vet Ophthalmol. 5th ed. Ames, Iowa: Wiley-Blackwell; 2013.  976-
1049. 
4. Tolar EL, Hendrix DV, Rohrbach BW, et al. Evaluation of clinical characteristics and 
bacterial isolates in dogs with bacterial keratitis: 97 cases (1993-2003). J Am Vet Med Assoc. 2006; 
228(1): 80-85. 
5. Stiles J. Feline Ophthalmology. In: Gelatt KN, Gilger BC, Kern TJ, editors. Vet Ophthalmol. 
5th ed. Ames, Iowa: Wiley-Blackwell; 2013. 1477-1559. 
6. Gilger BC. Equine Ophthalmology. In: Gelatt KN, Gilger BC, Kern TJ, editors. Vet 
Ophthalmol. 5th ed. Ames, Iowa: Wiley-Blackwell; 2013. 1560-1609. 
7. Brooks DE, Mattews A, Clode A. Diseases of the cornea. In: Gilger BC, editor. Equine 
ophthalmology. Third edition. ed. Ames, Iowa: Wiley Blackwell; 2017. 252-368. 
8. Massa KL, Murphy CJ, Hartmann FA, et al. Usefulness of aerobic microbial culture and 
cytologic evaluation of corneal specimens in the diagnosis of infectious ulcerative keratitis in animals. 
J Am Vet Med Assoc. 1999; 215(11): 1671-1674. 
9. Gerding PA, Jr., Kakoma I. Microbiology of the canine and feline eye. Vet Clin North Am 
Small Anim Pract. 1990; 20(3): 615-625. 
10. Ollivier FJ. Bacterial corneal diseases in dogs and cats. Clin Tech Small Anim Pract. 2003; 
18(3): 193-198. 
11. Stiles J. Ocular Infections. In: Greene CE, editor. Infectious diseases of the dog and cat. 4th 
ed. St. Louis, Mo.: Elsevier/Saunders; 2012. 1058-1077. 
12. Gerding PA, Jr., McLaughlin SA, Troop MW. Pathogenic bacteria and fungi associated with 
external ocular diseases in dogs: 131 cases (1981-1986). J Am Vet Med Assoc. 1988; 193(2): 242-
244. 
13. Wang L, Pan Q, Zhang L, et al. Investigation of bacterial microorganisms in the conjunctival 
sac of clinically normal dogs and dogs with ulcerative keratitis in Beijing, China. Vet Ophthalmol. 
2008; 11(3): 145-149. 
14. Morales A. VMAR, Salvadego M., Levy C.E. Microbiological and Clinical Aspects of 
Corneal Ulcers in Dogs. World Small Animal Veterinary Association World Congress Proceedings. 
2009. 
15. Lin CT, Petersen-Jones SM. Antibiotic susceptibility of bacteria isolated from cats with 
ulcerative keratitis in Taiwan. J Small Anim Pract. 2008; 49(2): 80-83. 
16. Espinola MB, Lilenbaum W. Prevalence of bacteria in the conjunctival sac and on the eyelid 
margin of clinically normal cats. J Small Anim Pract. 1996; 37(8): 364-366. 
17. Gerding PA, Cormany K, Weisiger R, et al. Survey and Topographic Distribution of Bacterial 
and Fungal Microorganisms in Eyes of Clinically Normal Cats. Feline Practice. 1993; 21(3): 20-23. 
18. Gaskin JM. Microbiology of the canine and feline eye. Vet Clin North Am Small Anim Pract. 
1980; 10(2): 303-316. 
19. Wada S, Hobo S, Niwa H. Ulcerative keratitis in thoroughbred racehorses in Japan from 1997 
to 2008. Vet Ophthalmol. 2010; 13(2): 99-105. 
	 21	
20. Sauer P, Andrew SE, Lassaline M, et al. Changes in antibiotic resistance in equine bacterial 
ulcerative keratitis (1991-2000): 65 horses. Vet Ophthalmol. 2003; 6(4): 309-313. 
21. Ollivier FJ, Brooks DE, Kallberg ME, et al. Evaluation of various compounds to inhibit 
activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. Am J Vet Res. 
2003; 64(9): 1081-1087. 
22. Brooks DE, Ollivier FJ. Matrix metalloproteinase inhibition in corneal ulceration. Vet Clin 
North Am Small Anim Pract. 2004; 34(3): 611-622. 
23. Suter A, Voelter K, Hartnack S, et al. Septic keratitis in dogs, cats, and horses in Switzerland: 
associated bacteria and antibiotic susceptibility. Vet Ophthalmol. 2017. 
24. Varges R, Penna B, Martins G, et al. Antimicrobial susceptibility of Staphylococci isolated 
from naturally occurring canine external ocular diseases. Vet Ophthalmol. 2009; 12(4): 216-220. 
25. Dowling PM. Antimicrobial Therapy of Selected Organs; Infections of the Eyes: 
Conjunctivitis, Keratitis, and Endophthalmitis. In: Gigue ̀re S, Prescott, J.F., Dowling, P.M., editor. 
Antimicrobial therapy in veterinary medicine. 5th ed. Ames, Iowa: Blackwell Pub.; 2013. 401-405. 
26. Gigue ̀re S, Prescott JF, Dowling PM. Antimicrobial therapy in veterinary medicine. 5th ed. 
Ames, Iowa, USA: Wiley Blackwell; 2013. xvii, 683 p. p. 
27. Ledbetter EC, Hendricks LM, Riis RC, et al. In vitro fluoroquinolone susceptibility of 
Pseudomonas aeruginosa isolates from dogs with ulcerative keratitis. Am J Vet Res. 2007; 68(6): 638-
642. 
28. WHO WHO. Antimicrobial resistance: global report on surveillance. 2014. 
29. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida 
and emerging resistance to fluoroquinolones. Ophthalmology. 2000; 107(8): 1497-1502. 
30. Chalita MR, Hofling-Lima AL, Paranhos A, Jr., et al. Shifting trends in in vitro antibiotic 
susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004; 
137(1): 43-51. 
31. Sharma V, Sharma S, Garg P, et al. Clinical resistance of Staphylococcus keratitis to 
ciprofloxacin monotherapy. Indian J Ophthalmol. 2004; 52(4): 287-292. 
32. Kunimoto DY, Sharma S, Garg P, et al. In vitro susceptibility of bacterial keratitis pathogens 
to ciprofloxacin. Emerging resistance. Ophthalmology. 1999; 106(1): 80-85. 
33. Gigue ̀re SD, P.M. Fluoroquinolones.  Antimicrobial Therapy in Veterinary Medicine. 5th ed. 
Ames, Iowa, USA: Wiley Blackwell; 2013. 295-314. 
34. Dowling PM. Aminoglycosides and Aminocyclitols.  Antimicrobial Therapy in Veterinary 
Medicine. 5th ed. Ames, Iowa, USA: Wiley Blackwell; 2013. 233-255. 
35. Keller RL, Hendrix DV. Bacterial isolates and antimicrobial susceptibilities in equine bacterial 
ulcerative keratitis (1993--2004). Equine Vet J. 2005; 37(3): 207-211. 
36. Prescott JF. Beta-lactam Antibiotics: Cephalosporins. In: Gigue ̀re S, Prescott JF, Dowling PM, 
editors. Antimicrobial therapy in veterinary medicine. 5th ed. Ames, Iowa, USA: Wiley Blackwell; 
2013. 153-174. 
37. Dowling PM. Miscellaneous Antimicrobials: Ionophores, Nitrofurans, Nitroimidazoles, 
Rifamycins and Others. In: Gigue ̀re S, Prescott JF, Dowling PM, editors. Antimicrobial therapy in 
veterinary medicine. 5th ed. Ames, Iowa, USA: Wiley Blackwell; 2013. 315-332. 
38. Hariharan H, Coles M, Poole D, et al. Update on antimicrobial susceptibilities of bacterial 
isolates from canine and feline otitis externa. Can Vet J. 2006; 47(3): 253-255. 
39. Dowling PM. Peptide Antibiotics: Polymyxins, Glycopeptides, Bacitracin and Fosfomycin. In: 
Gigue ̀re S, Prescott JF, Dowling PM, editors. Antimicrobial therapy in veterinary medicine. 5th ed. 
Ames, Iowa, USA: Wiley Blackwell; 2013. 189-198. 
40. Pot SA, Gallhofer NS, Matheis FL, et al. Corneal collagen cross-linking as treatment for 
infectious and noninfectious corneal melting in cats and dogs: results of a prospective, 
nonrandomized, controlled trial. Vet Ophthalmol. 2013. 
41. Hakanson N MR. Further comments on conjunctival pedicle grafting in the treatment of 
corneal ulcers in the dog and cat. Journal of the American Animal Hospital Association. 1988; 24: 
602-605. 
42. Hakanson N MR. Conjunctival pedicle grafting in the  treatment of corneal ulcers in the dog 
and cat. Journal of the American Animal Hospital Association. 1987; 23: 641-648. 
43. Wollensak G, Sporl E, Seiler T. [Treatment of keratoconus by collagen cross linking]. 
Ophthalmologe. 2003; 100(1): 44-49. 
	 22	
44. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for 
the treatment of keratoconus. Am J Ophthalmol. 2003; 135(5): 620-627. 
45. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic 
digestion. Curr Eye Res. 2004; 29(1): 35-40. 
46. Corbin F, 3rd. Pathogen inactivation of blood components: current status and introduction of 
an approach using riboflavin as a photosensitizer. Int J Hematol. 2002; 76 Suppl 2: 253-257. 
47. Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA 
combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for 
infectious keratitis. Invest Ophthalmol Vis Sci. 2008; 49(8): 3402-3408. 
48. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin 
and ultraviolet light for pathogen reduction. Transfusion. 2005; 45(8): 1335-1341. 
49. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox 
Sang. 2000; 78 Suppl 2: 211-215. 
50. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: 
extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004; 80:15-
21. 
51. Wollensak G, Spoerl E, Reber F, et al. Keratocyte cytotoxicity of riboflavin/UVA-treatment in 
vitro. Eye (Lond). 2004; 18(7): 718-722. 
52. McAteer MJ, Tay-Goodrich BH, Doane S, et al. Photoinactivation of virus in packed red 
blood cell units using riboflavin and visible light. Transfusion. 2000; 40(10): 99s-99s. 
53. Uc MH, Scott JF. Effects of ultraviolet light on the biological functions of transfer RNA. 
Biochem Biophys Res Commun. 1966; 22(5): 459-465. 
54. Chan TC, Agarwal T, Vajpayee RB, et al. Cross-linking for microbial keratitis. Curr Opin 
Ophthalmol. 2016; 27(4): 348-352. 
55. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas 
after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003; 29(9): 1780-1785. 
56. Dhaliwal JS, Kaufman SC. Corneal collagen cross-linking: a confocal, electron, and light 
microscopy study of eye bank corneas. Cornea. 2009; 28(1): 62-67. 
57. Mazzotta C, Balestrazzi A, Traversi C, et al. Treatment of progressive keratoconus by 
riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg 
Retinal Tomograph II in vivo confocal microscopy in humans. Cornea. 2007; 26(4): 390-397. 
58. Hafezi F, Kanellopoulos J, Wiltfang R, et al. Corneal collagen crosslinking with riboflavin and 
ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg. 
2007; 33(12): 2035-2040. 
59. Kamburoglu G, Ertan A. Intacs implantation with sequential collagen cross-linking treatment 
in postoperative LASIK ectasia. J Refract Surg. 2008; 24(7): S726-729. 
60. Kohlhaas M, Spoerl E, Speck A, et al. [A new treatment of keratectasia after LASIK by using 
collagen with riboflavin/UVA light cross-linking]. Klin Monbl Augenheilkd. 2005; 222(5): 430-436. 
61. Wollensak G, Aurich H, Pham DT, et al. Hydration behavior of porcine cornea crosslinked 
with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007; 33(3): 516-521. 
62. Bottos KM, Dreyfuss JL, Regatieri CV, et al. Immunofluorescence confocal microscopy of 
porcine corneas following collagen cross-linking treatment with riboflavin and ultraviolet A. J Refract 
Surg. 2008; 24(7): S715-719. 
63. Ehlers N, Hjortdal J. Riboflavin-ultraviolet light induced cross-linking in endothelial 
decompensation. Acta Ophthalmol. 2008; 86(5): 549-551. 
64. Wollensak G, Aurich H, Wirbelauer C, et al. Potential use of riboflavin/UVA cross-linking in 
bullous keratopathy. Ophthalmic Res. 2009; 41(2): 114-117. 
65. Krueger RR, Ramos-Esteban JC, Kanellopoulos AJ. Staged intrastromal delivery of riboflavin 
with UVA cross-linking in advanced bullous keratopathy: laboratory investigation and first clinical 
case. J Refract Surg. 2008; 24(7): S730-736. 
66. Anwar HM, El-Danasoury AM, Hashem AN. Corneal collagen crosslinking in the treatment 
of infectious keratitis. Clin Ophthalmol. 2011; 5: 1277-1280. 
67. Makdoumi K, Mortensen J, Sorkhabi O, et al. UVA-riboflavin photochemical therapy of 
bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012; 250(1): 95-102. 
68. Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. 
Cornea. 2010; 29(12): 1353-1358. 
	 23	
69. Moren H, Malmsjo M, Mortensen J, et al. Riboflavin and Ultraviolet A Collagen Crosslinking 
of the Cornea for the Treatment of Keratitis. Cornea. 2010; 29(1): 102-104. 
70. Iseli HP, Thiel MA, Hafezi F, et al. Ultraviolet A/riboflavin corneal cross-linking for 
infectious keratitis associated with corneal melts. Cornea. 2008; 27(5): 590-594. 
71. Micelli Ferrari T, Leozappa M, Lorusso M, et al. Escherichia coli keratitis treated with 
ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol. 2009; 19(2): 295-297. 
72. Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light a therapy as 
an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. 
Ophthalmology. 2011; 118(2): 324-331. 
73. Schrier A, Greebel G, Attia H, et al. In vitro antimicrobial efficacy of riboflavin and 
ultraviolet light on Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and 
Pseudomonas aeruginosa. J Refract Surg. 2009; 25(9): S799-802. 
74. Makdoumi K, Backman A, Mortensen J, et al. Evaluation of antibacterial efficacy of photo-
activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol. 2010; 248(2): 
207-212. 
75. Richoz O, Kling S, Hoogewoud F, et al. Antibacterial efficacy of accelerated photoactivated 
chromophore for keratitis-corneal collagen cross-linking (PACK-CXL). J Refract Surg. 2014; 30(12): 
850-854. 
76. Schnitzler E, Sporl E, Seiler T. [Irradiation of cornea with ultraviolet light and riboflavin 
administration as a new treatment for erosive corneal processes, preliminary results in four patients]. 
Klin Monbl Augenheilkd. 2000; 217(3): 190-193. 
77. Snibson GR. Collagen cross-linking: a new treatment paradigm in corneal disease - a review. 
Clin Experiment Ophthalmol. 2010; 38(2): 141-153. 
78. Muller L, Thiel MA, Kipfer-Kauer AI, et al. Corneal cross-linking as supplementary treatment 
option in melting keratitis: a case series. Klin Monbl Augenheilkd. 2012; 229(4): 411-415. 
79. Famose F. Evaluation of accelerated collagen cross-linking for the treatment of melting 
keratitis in ten cats. Vet Ophthalmol. 2015; 18(2): 95-104. 
80. Famose F. Evaluation of accelerated collagen cross-linking for the treatment of melting 
keratitis in eight dogs. Vet Ophthalmol. 2014; 17(5): 358-367. 
81. Hellander-Edman A, Makdoumi K, Mortensen J, et al. Corneal cross-linking in 9 horses with 
ulcerative keratitis. BMC Vet Res. 2013; 9: 128. 
82. Price MO, Tenkman LR, Schrier A, et al. Photoactivated riboflavin treatment of infectious 
keratitis using collagen cross-linking technology. J Refract Surg. 2012; 28(10): 706-713. 
83. Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin 
(PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 
2014; 121(7): 1377-1382. 
84. Spiess BM, Pot SA, Florin M, et al. Corneal collagen cross-linking (CXL) for the treatment of 
melting keratitis in cats and dogs: a pilot study. Vet Ophthalmol. 2014; 17(1): 1-11. 
85. Gallhoefer NS, Spiess BM, Guscetti F, et al. Penetration depth of corneal cross-linking with 
riboflavin and UV-A (CXL) in horses and rabbits. Vet Ophthalmol. 2016; 19(4): 275-284. 
86. Berra M, Galperin G, Boscaro G, et al. Treatment of Acanthamoeba keratitis by corneal cross-
linking. Cornea. 2013; 32(2): 174-178. 
87. Galperin G, Berra M, Tau J, et al. Treatment of fungal keratitis from Fusarium infection by 
corneal cross-linking. Cornea. 2012; 31(2): 176-180. 
88. Kralik P, Babak V, Dziedzinska R. Repeated cycles of chemical and physical disinfection and 
their influence on Mycobacterium avium subsp. paratuberculosis viability measured by propidium 
monoazide F57 quantitative real time PCR. Vet J. 2014; 201(3): 359-364. 
89. Ermolaeva SA, Varfolomeev AF, Chernukha MY, et al. Bactericidal effects of non-thermal 
argon plasma in vitro, in biofilms and in the animal model of infected wounds. J Med Microbiol. 
2011; 60(Pt 1): 75-83. 
90. Wernli J, Schumacher S, Spoerl E, et al. The efficacy of corneal cross-linking shows a sudden 
decrease with very high intensity UV light and short treatment time. Invest Ophthalmol Vis Sci. 2013; 
54(2): 1176-1180. 
91. Richoz O, Hammer A, Tabibian D, et al. The Biomechanical Effect of Corneal Collagen 
Cross-Linking (CXL) With Riboflavin and UV-A is Oxygen Dependent. Transl Vis Sci Technol. 
2013;2(7):6. 
	 24	
92. Hammer A, Richoz O, Mosquera SA, et al. Corneal Biomechanical Properties at Different 
Corneal Cross-Linking (CXL) IrradiancesCorneal Biomechanics at Higher UV-A Irradiances. Invest 
Ophthalmol Vis Sci. 2014; 55(5): 2881-2884. 
93. Sun B, Li ZW, Yu HQ, et al. Evaluation of the in vitro antimicrobial properties of ultraviolet 
A/riboflavin mediated crosslinking on Candida albicans and Fusarium solani. Int J Ophthalmol. 2014; 
7(2): 205-210. 
94. Meile L. Comparison of the in vitro effect of two different corneal Crosslinking-Protocols on 
fungal growth [Doctoral]. Zürich: Universität Zürich; 2015. 
95. Kashiwabuchi RT, Carvalho FR, Khan YA, et al. Assessment of fungal viability after long-
wave ultraviolet light irradiation combined with riboflavin administration. Graefes Arch Clin Exp 
Ophthalmol. 2013; 251(2): 521-527. 
96. Makdoumi K, Backman A. Photodynamic UVA-riboflavin bacterial elimination in antibiotic-
resistant bacteria. Clin Exp Ophthalmol. 2016; 44(7): 582-586. 
97. Pinheiro J BD, DebRoy S, Sarkar D and R Core Team. _nlme: Linear and Nonlinear Mixed 
Effects Models_. R package version 3.1-128. 2016. 
98. Team RDC. R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria.; 2008. 		
 
 
9 Annex 
9.1 Abbreviations 
ATCC   American Type Culture Collection 
CFU   Colony forming unit 
CSB   Columbia Sheep Blood agar plate (Oxoid, Pratteln, Switzerland) 
CXL   Corneal Crosslinking 
EDTA   Disodium Ethylene-Diaminetetra-Acetic Acid 
FHV-1   Feline Herpes Virus 1 
IVB   Institute for Veterinary Bacteriology, University of Zürich 
KCS   Keratoconjunctivitis sicca 
MMP   Matrix-Metalloproteinase 
NaCl   Sodium Chloride 
PACK-CXL  Photoactivated Chromophore for infectious Keratitis – CXL 
Rpm   Revolutions per minute 
Spp.   Species pluralis 
UV-A   Ultraviolet A radiation 
Tested Groups   
  C Control 
  Ri Riboflavin only 
  UV UV-A only 
  Ri/UV Riboflavin and UV-A in combination 		
	 25	
9.2 Tables main experiments: CFU and bacterial concentration  
Iso
la
te
Iso
la
te
_I
D
Re
p_
Nr
Tr
ea
tm
en
t
Di
lu
tio
n_
1a
Di
lu
tio
n_
1b
Di
lu
tio
n_
1M
V
Di
lu
tio
n_
2a
Di
lu
tio
n_
2b
Di
lu
tio
n_
2M
V
M
icr
ob
es
_p
er
_3
0u
L
De
cr
ea
se
_I
nc
re
as
e_
%
Da
te
UV
>E
m
iss
io
n
Di
lu
tio
n_
Nu
m
be
r
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
1
C_
30
M
in
78
87
82
.5
13
11
12
12
80
0
>7
1.
55
08
.1
1.
16
3.
03
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
1
Ri
UV
_3
m
W
82
66
74
8
6
7
11
00
0
>7
5.
55
%
08
.1
1.
16
3.
03
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
2
C_
30
M
in
10
5
12
2
11
3.
5
12
11
11
.5
17
04
0
>6
2.
13
%
09
.1
1.
16
2.
87
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
2
Ri
UV
_3
m
W
75
87
81
11
6
8.
5
12
20
0
>7
2.
85
%
09
.1
1.
16
2.
87
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
1B
C_
5M
in
11
8
12
5
12
1.
5
13
12
12
.5
18
27
0
>5
9.
40
%
23
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
1B
Ri
UV
_1
8m
W
13
2
15
7
14
4.
5
22
9
15
.5
21
81
6
>5
1.
52
23
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
2B
C_
5M
in
24
9
22
1
23
5
20
18
19
34
63
5
>2
3.
03
07
/1
2/
16
18
3&
4
S.
ep
id
er
m
id
is
7_
S.
ep
id
er
m
id
is
2B
Ri
UV
_1
8m
W
14
6
13
9
14
2.
5
17
12
14
.5
21
40
8
>5
2.
42
07
/1
2/
16
18
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
1
C_
30
M
in
93
82
87
.5
7
8
7.
5
12
90
0
>7
1.
33
%
08
.1
1.
16
3.
03
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
1
Ri
UV
_3
m
W
71
73
72
11
7
9
11
00
0
>7
5.
55
%
08
.1
1.
16
3.
03
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
2
C_
30
M
in
86
81
83
.5
10
8
9
12
61
0
>7
1.
97
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
2
Ri
UV
_3
m
W
52
49
50
.5
5
3
4
74
10
>8
3.
53
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
1B
C_
5M
in
14
1
14
4
14
2.
5
15
17
16
21
61
3
>5
1.
97
24
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
1B
Ri
UV
_1
8m
W
72
89
80
.5
5
9
7
11
93
1
>7
3.
97
24
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
2B
C_
5M
in
13
1
14
7
13
9
12
10
11
20
45
4
>5
4.
55
29
/1
1/
16
18
3&
4
S.
ep
id
er
m
id
is
6_
S.
ep
id
er
m
id
is
2B
Ri
UV
_1
8m
W
12
6
98
11
2
7
6
6.
5
16
15
8
>6
4.
1
29
/1
1/
16
18
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
1
C_
30
M
in
67
69
68
6
8
7
10
20
0
>7
7.
33
%
9.
11
.1
6
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
1
Ri
UV
_3
m
W
26
17
21
.5
3
4
3.
5
34
08
>9
2.
42
%
9.
11
.1
6
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
2
C_
30
M
in
12
3
72
97
.5
9
6
7.
5
14
30
0
>6
8.
22
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
2
Ri
UV
_3
m
W
50
64
57
8
9
8.
5
89
30
>8
0.
16
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
1B
C_
5M
in
11
2
12
0
11
6
11
4
7.
5
16
84
0
>6
2.
57
24
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
1B
Ri
UV
_1
8m
W
68
72
70
6
3
4.
5
10
15
8
>7
7.
42
24
.1
1.
16
18
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
2B
C_
5M
in
10
0
10
0
10
0
4
5
4.
5
14
25
0
>6
8.
33
29
/1
1/
16
18
3&
4
S.
ep
id
er
m
id
is
24
_S
.e
pi
de
rm
id
is_
M
RS
A+
2B
Ri
UV
_1
8m
W
97
91
94
6
4
5
13
50
0
>7
0
29
/1
1/
16
18
3&
4
S.
au
re
us
4_
S.
au
re
us
1
C_
30
M
in
11
1
11
6
11
3.
5
11
6
8.
5
16
63
0
>6
3.
04
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
au
re
us
4_
S.
au
re
us
1
Ri
UV
_3
m
W
64
71
67
.5
8
2
5
98
80
>7
8.
04
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
au
re
us
4_
S.
au
re
us
2
C_
30
M
in
13
9
12
9
13
4
15
15
15
20
31
0
>5
4.
86
8
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
au
re
us
4_
S.
au
re
us
2
Ri
UV
_3
m
W
88
76
82
8
5
6.
5
11
86
0
>7
3.
64
4
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
au
re
us
4_
S.
au
re
us
1B
C_
5M
in
11
9
11
7
11
8
9
12
10
.5
17
52
2
>6
1
23
.1
1.
16
18
4&
5
S.
au
re
us
4_
S.
au
re
us
1B
Ri
UV
_1
8m
W
67
74
70
.5
7
7
7
10
56
8
>7
6.
52
23
.1
1.
16
18
4&
5
S.
au
re
us
4_
S.
au
re
us
2B
C_
5M
in
13
7
14
4
14
0.
5
20
8
14
21
06
8
>5
3.
19
29
/1
1/
16
18
4&
5
S.
au
re
us
4_
S.
au
re
us
2B
Ri
UV
_1
8m
W
63
54
58
.5
7
7
7
89
31
>8
0.
16
29
/1
1/
16
18
4&
5
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
1
C_
30
M
in
28
4
29
2
28
8
25
38
31
.5
43
50
0
>3
.2
8%
08
.1
1.
16
3.
03
3&
4
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
1
Ri
UV
_3
m
W
14
0
16
0
15
0
18
15
16
.5
20
65
0
>5
4.
11
%
08
.1
1.
16
3.
03
3&
4
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
2
C_
30
M
in
25
7
24
9
25
3
33
27
30
38
58
0
>1
4.
23
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
2
Ri
UV
_3
m
W
20
1
19
3
19
7
23
15
19
29
45
0
>3
4.
55
%
10
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
1B
C_
5M
in
31
40
35
.5
3
4
3.
5
53
18
>8
8.
19
24
.1
1.
16
18
4&
5
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
1B
Ri
UV
_1
8m
W
24
30
27
0
0
0
36
81
>9
1.
2
24
.1
1.
16
18
4&
5
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
2B
C_
5M
in
46
47
46
.5
3
10
6.
5
72
27
>8
3.
94
29
/1
1/
16
18
4&
5
S.
au
re
us
23
_S
.a
ur
eu
s_
M
RS
A+
2B
Ri
UV
_1
8m
W
19
21
20
5
1
3
31
36
>9
3.
03
29
/1
1/
16
18
4&
5
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
1
C_
30
M
in
56
57
56
.5
4
11
7.
5
87
20
>8
0.
62
%
08
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
1
Ri
UV
_3
m
W
40
55
47
.5
3
2
2.
5
68
16
>8
4.
85
%
08
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
2
C_
30
M
in
45
38
41
.5
3
6
4.
5
62
72
>8
6.
06
%
09
.1
1.
16
2.
87
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
2
Ri
UV
_3
m
W
31
34
32
.5
5
4
4.
5
50
43
>8
8.
79
%
09
.1
1.
16
2.
87
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
1B
C_
5M
in
89
75
82
6
5
5.
5
11
93
1
>7
3.
48
24
.1
1.
16
18
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
1B
Ri
UV
_1
8m
W
16
40
28
1
3
2
40
90
>9
0.
91
24
.1
1.
16
18
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
2B
C_
5M
in
98
84
91
8
5
6.
5
13
29
5
>7
0.
46
29
/1
1/
16
18
3&
4
S.
ha
em
ol
yt
icu
s
11
_S
.h
ae
m
ol
yt
ic
us
_M
RS
A+
2B
Ri
UV
_1
8m
W
65
64
64
.5
9
6
7.
5
98
18
>7
8.
18
29
/1
1/
16
18
3&
4
	 26		
S.
le
nt
us
13
_S
.le
nt
us
1
C_
30
M
in
89
70
79
.5
6
8
7
11
79
0
>7
3.
81
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
le
nt
us
13
_S
.le
nt
us
1
Ri
U
V_
3m
W
50
59
54
.5
10
5
7.
5
84
54
>8
1.
22
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
le
nt
us
13
_S
.le
nt
us
2
C_
30
M
in
78
89
83
.5
5
12
8.
5
12
54
0
>7
2.
14
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
le
nt
us
13
_S
.le
nt
us
2
Ri
U
V_
3m
W
79
99
89
6
9
7.
5
13
15
0
>7
0.
78
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
le
nt
us
13
_S
.le
nt
us
1B
C_
5M
in
89
10
8
98
.5
11
15
13
15
20
4
>6
6.
22
24
.1
1.
16
18
4&
5
S.
le
nt
us
13
_S
.le
nt
us
1B
Ri
U
V_
18
m
W
83
11
2
97
.5
7
10
8.
5
14
45
4
>6
7.
88
24
.1
1.
16
18
4&
5
S.
le
nt
us
13
_S
.le
nt
us
2B
C_
5M
in
93
98
95
.5
8
16
12
14
65
8
>6
7.
42
29
/1
1/
16
18
4&
5
S.
le
nt
us
13
_S
.le
nt
us
2B
Ri
U
V_
18
m
W
96
10
0
98
11
6
8.
5
14
52
2
>6
7.
73
29
/1
1/
16
18
4&
5
S.
le
nt
us
13
_S
.le
nt
us
3B
C_
5M
in
10
3
79
91
9
10
9.
5
13
70
4
>6
9.
55
07
/1
2/
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
le
nt
us
13
_S
.le
nt
us
3B
Ri
U
V_
18
m
W
85
89
87
6
9
7.
5
12
88
6
>7
1.
37
07
/1
2/
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
1
C_
30
M
in
15
9
14
0
14
9.
5
16
9
12
.5
22
08
0
>5
0.
93
%
09
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
1
Ri
U
V_
3m
W
90
10
0
95
4
10
7
13
90
0
>6
9.
11
%
09
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
2
C_
30
M
in
48
47
47
.5
3
2
2.
5
68
18
>8
4.
85
10
/1
1/
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
2
Ri
U
V_
3m
W
32
31
31
.5
1
0
0.
5
43
63
>9
0.
30
5
10
/1
1/
16
De
vi
ce
Od
ef
ec
t
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
1B
C_
5M
in
28
28
28
6
3
4.
5
44
31
>9
0.
16
24
.1
1.
16
18
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
1B
Ri
U
V_
18
m
W
22
35
28
.5
3
1
2
41
58
>9
0.
76
24
.1
1.
16
18
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
2B
C_
5M
in
15
21
18
0
1
0.
5
25
22
>9
4.
39
07
/1
2/
16
18
4&
5
S.
ps
eu
di
nt
er
m
ed
iu
s
29
_S
.p
se
ud
in
te
rm
ed
iu
s
2B
Ri
U
V_
18
m
W
11
11
11
0
1
0.
5
15
68
>9
6.
51
07
/1
2/
16
18
4&
5
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
1
C_
30
M
in
23
28
25
.5
5
5
5
41
58
>9
0.
76
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
1
Ri
U
V_
3m
W
22
14
18
2
2
2
27
27
>9
3.
94
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
2
C_
30
M
in
22
27
24
.5
3
5
4
38
85
>9
1.
36
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
2
Ri
U
V_
3m
W
16
18
17
1
2
1.
5
25
22
>9
4.
39
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
1B
C_
5M
in
56
50
53
11
4
7.
5
27
50
>9
3.
88
30
/1
1/
16
18
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
1B
Ri
U
V_
18
m
W
35
29
32
2
0
1
45
0
>9
9
30
/1
1/
16
18
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
2B
C_
5M
in
10
8
73
90
.5
7
11
9
13
56
8
>6
9.
85
06
/1
2/
16
18
3&
4
St
.d
ys
ga
la
ct
ia
e
3_
St
.d
ys
ga
la
ct
ia
e_
eq
ui
si
m
ili
s
2B
Ri
U
V_
18
m
W
52
42
47
3
4
3.
5
68
86
>8
4.
7
06
/1
2/
16
18
3&
4
St
.c
an
is
8_
St
.c
an
is
1
C_
30
M
in
21
7
24
5
23
1
31
25
28
35
31
0
>2
1.
53
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
8_
St
.c
an
is
1
Ri
U
V_
3m
W
11
2
13
5
12
3.
5
3
9
6
17
65
0
>6
0.
77
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
8_
St
.c
an
is
3
C_
30
M
in
14
15
14
.5
3
0
1.
5
21
81
>9
5.
15
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
St
.c
an
is
8_
St
.c
an
is
3
Ri
U
V_
3m
W
4
6
5
2
0
1
81
8
>9
8.
18
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
St
.c
an
is
8_
St
.c
an
is
1B
C_
5M
in
21
23
22
1
2
1.
5
32
04
>9
2.
88
30
/1
1/
16
18
4&
5
St
.c
an
is
8_
St
.c
an
is
1B
Ri
U
V_
18
m
W
15
10
12
.5
0
0
0
17
04
>9
6.
21
30
/1
1/
16
18
4&
5
St
.c
an
is
8_
St
.c
an
is
2B
C_
5M
in
44
52
48
4
7
5.
5
72
93
>8
3.
79
06
/1
2/
16
18
4&
5
St
.c
an
is
8_
St
.c
an
is
2B
Ri
U
V_
18
m
W
18
27
22
.5
1
4
2.
5
34
08
>9
2.
42
06
/1
2/
16
18
4&
5
St
.c
an
is
17
_S
t.c
an
is
1
C_
30
M
in
74
88
81
8
5
6.
5
11
93
1
>7
3.
48
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
17
_S
t.c
an
is
1
Ri
U
V_
3m
W
33
44
38
.5
4
5
4.
5
58
63
>8
6.
97
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
17
_S
t.c
an
is
2
C_
30
M
in
26
23
24
.5
5
3
4
38
86
>9
1.
36
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
17
_S
t.c
an
is
2
Ri
U
V_
3m
W
14
18
16
1
1
1
23
18
>9
4.
84
17
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
17
_S
t.c
an
is
1B
C_
5M
in
74
58
66
1
1
1
91
36
>7
9.
7
30
/1
1/
16
18
3&
4
St
.c
an
is
17
_S
t.c
an
is
1B
Ri
U
V_
18
m
W
35
38
36
.5
0
3
1.
5
51
81
>8
8.
48
30
/1
1/
16
18
3&
4
St
.c
an
is
17
_S
t.c
an
is
2B
C_
5M
in
11
3
10
2
10
7.
5
11
6
8.
5
15
81
8
>6
4.
85
06
/1
2/
16
18
3&
4
St
.c
an
is
17
_S
t.c
an
is
2B
Ri
U
V_
18
m
W
54
54
54
4
5
4.
5
79
77
>8
2.
28
06
/1
2/
16
18
3&
4
St
.c
an
is
28
_S
t.c
an
is
1
C_
30
M
in
74
88
81
8
5
6.
5
11
93
1
>7
3.
48
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
28
_S
t.c
an
is
1
Ri
U
V_
3m
W
33
44
38
.5
4
5
4.
5
58
63
>8
6.
97
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
28
_S
t.c
an
is
2
C_
30
M
in
10
3
94
98
.5
8
5
6.
5
14
31
8
>6
8.
18
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
28
_S
t.c
an
is
2
Ri
U
V_
3m
W
35
37
36
1
0
0.
5
49
77
>8
8.
94
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.c
an
is
28
_S
t.c
an
is
1B
C_
5M
in
17
5
15
6
16
5.
5
22
7
14
.5
24
54
5
>4
5.
45
30
/1
1/
16
18
3&
4
St
.c
an
is
28
_S
t.c
an
is
1B
Ri
U
V_
18
m
W
90
91
90
.5
8
8
8
13
43
1
>7
0.
15
31
.1
1.
16
18
3&
4
St
.c
an
is
28
_S
t.c
an
is
2B
C_
5M
in
10
8
11
2
11
0
10
8
9
16
22
7
>6
3.
94
06
/1
2/
16
18
3&
4
	 27	
 
St
.c
an
is
28
_S
t.c
an
is
2B
Ri
U
V_
18
m
W
69
69
69
5
2
3.
5
98
85
>7
8.
03
06
/1
2/
16
18
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
1
C_
30
M
in
64
63
63
.5
5
12
8.
5
98
16
>7
8.
18
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
1
Ri
U
V_
3m
W
19
30
24
.5
2
1
1.
5
35
45
>9
2.
12
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
2
C_
30
M
in
11
2
11
7
11
4.
5
8
11
9.
5
16
90
9
>6
2.
42
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
2
Ri
U
V_
3m
W
41
40
40
.5
7
3
5
62
04
>8
6.
21
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
1B
C_
5M
in
15
6
15
0
15
3
17
17
17
23
18
1
>4
8.
48
30
/1
1/
16
18
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
1B
Ri
U
V_
18
m
W
11
4
11
8
11
6
7
10
8.
5
16
97
7
>6
2.
28
30
/1
1/
16
18
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
2B
C_
5M
in
16
5
18
0
17
2.
5
14
19
16
.5
25
77
2
>4
2.
73
06
/1
2/
16
18
3&
4
St
.e
qu
i
12
_S
t.e
qu
i_
ss
p_
zo
oe
pi
de
m
ic
us
2B
Ri
U
V_
18
m
W
89
96
92
.5
8
15
11
.5
14
18
1
>6
8.
48
06
/1
2/
16
18
3&
4
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
1
C_
30
M
in
10
5
89
97
6
10
8
14
31
0
>6
8.
2
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
1
Ri
U
V_
3m
W
34
35
34
.5
0
0
0
47
04
>8
9.
55
15
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
2
C_
30
M
in
53
56
54
.5
11
6
8.
5
85
90
>8
0.
92
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
2
Ri
U
V_
3m
W
46
36
41
6
6
6
64
09
>8
5.
75
22
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
1B
C_
5M
in
13
3
15
9
14
6
14
11
12
.5
21
61
3
>5
1.
97
01
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
1B
Ri
U
V_
18
m
W
11
3
11
6
11
4.
5
12
9
10
.5
17
04
3
>6
2.
12
01
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
2B
C_
5M
in
84
70
77
3
7
5
11
18
1
>7
5.
15
06
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
14
_P
.a
er
ug
in
os
a
2B
Ri
U
V_
18
m
W
62
64
63
7
3
5
92
72
>7
9.
4
06
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
1
C_
30
M
in
15
3
19
0
17
1.
5
18
24
21
26
25
0
>4
1.
66
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
1
Ri
U
V_
3m
W
75
79
77
6
5
5.
5
11
25
0
>7
5
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
2
C_
30
M
in
32
29
30
.5
1
3
2
44
31
>9
0.
15
06
/1
2/
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
2
Ri
U
V_
3m
W
23
20
21
.5
5
1
3
33
40
>9
2.
57
06
/1
2/
16
De
vi
ce
Od
ef
ec
t
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
1B
C_
5M
in
76
57
66
.5
7
9
8
10
15
8
>7
7.
42
01
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
1B
Ri
U
V_
18
m
W
42
58
50
3
4
3.
5
72
95
>8
3.
78
01
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
2B
C_
5M
in
62
70
66
5
7
6
98
18
>7
8.
18
06
/1
2/
16
18
4&
5
P.
ae
ru
gi
no
sa
21
_P
.a
er
ug
in
os
a
2B
Ri
U
V_
18
m
W
47
41
44
2
3
2.
5
63
40
>8
5.
91
07
/1
2/
16
18
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
1
C_
30
M
in
13
5
13
6
13
5.
5
13
13
13
20
25
0
>5
5
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
1
Ri
U
V_
3m
W
39
53
46
6
5
5.
5
70
22
>8
4.
4
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
2
C_
30
M
in
19
0
21
6
20
3
11
21
16
29
86
3
>3
3.
63
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
2
Ri
U
V_
3m
W
67
65
66
8
10
9
10
22
7
>7
7.
27
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
1B
C_
5M
in
25
9
25
0
19
2
18
31
33
.5
30
75
0
>3
1.
66
01
/1
2/
16
18
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
1B
Ri
U
V_
18
m
W
85
92
88
.5
9
11
10
13
43
1
>7
0.
15
01
/1
2/
16
18
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
2B
C_
5M
in
19
7
15
8
17
7.
5
16
10
13
25
97
7
>4
2.
28
07
/1
2/
16
18
4&
5
Pa
st
.m
ul
to
ci
da
16
_P
as
t.m
ul
to
ci
da
2B
Ri
U
V_
18
m
W
90
10
6
98
7
8
7.
5
14
38
6
>6
8.
04
07
/1
2/
16
18
4&
5
Pa
st
.c
an
is
18
_P
as
t.c
an
is
1
C_
30
M
in
58
64
61
5
7
6
91
35
>7
9.
7
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
1
Ri
U
V_
3m
W
25
11
18
2
1
1.
5
26
58
>9
4.
09
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
2
C_
30
M
in
15
2
17
6
16
4
16
17
16
.5
24
61
3
>4
5.
31
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
2
Ri
U
V_
3m
W
10
0
10
0
10
0
9
7
8
14
72
7
>6
7.
27
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
1B
C_
5M
in
80
93
86
.5
3
3
3
12
20
4
>7
2.
88
01
/1
2/
16
18
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
1B
Ri
U
V_
18
m
W
39
26
32
.5
3
4
3.
5
49
08
>8
9.
1
01
/1
2/
16
18
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
2B
C_
5M
in
53
63
58
1
1
1
80
54
>8
2.
11
07
/1
2/
16
18
3&
4
Pa
st
.c
an
is
18
_P
as
t.c
an
is
2B
Ri
U
V_
18
m
W
27
30
28
.5
1
4
2.
5
42
27
>9
0.
61
07
/1
2/
16
18
3&
4
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
1
C_
30
M
in
53
61
57
5
4
4.
5
83
85
>8
1.
36
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
1
Ri
U
V_
3m
W
26
21
23
.5
2
4
3
36
12
>9
1.
98
16
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
2
C_
30
M
in
59
34
46
.5
4
4
4
68
86
>8
4.
7
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
2
Ri
U
V_
3m
W
10
4
7
2
2
2
12
27
>9
7.
27
23
.1
1.
16
De
vi
ce
Od
ef
ec
t
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
1B
C_
5M
in
72
73
72
.5
8
10
9
11
11
3
>7
5.
31
01
/1
2/
16
18
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
1B
Ri
U
V_
18
m
W
25
35
30
1
2
1.
5
42
95
>9
0.
45
01
/1
2/
16
18
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
2B
C_
5M
in
52
50
51
8
10
9
81
81
>8
1.
82
07
/1
2/
16
18
4&
5
Pa
st
.d
ag
m
at
is
30
_P
as
t.d
ag
m
at
is
2B
Ri
U
V_
18
m
W
19
24
21
.5
4
0
2
32
04
>9
2.
88
07
/1
2/
16
18
4&
5
Curriculum vitae 
 
Vorname Name Anja Suter 
Geburtsdatum 7. Januar 1989 
Geburtsort Winterthur ZH 
Nationalität Schweiz 
Heimatort Suhr AG 
 
 
 
2001-2007:  1.-6. Langzeitgymnasium KZU Bülach 
  
Juli 2007 Abschluss Eidgenössische Maturität 
  
2009-2015 Studium der Veterinärmedizin an der Vetsuisse 
Fakultät Zürich, Universität Zürich, Schweiz 
  
Januar 2016 Abschluss med. vet. an der Vetsuisse Fakultät Zürich, 
UZH, Schweiz 
  
März 2016 – Januar 2017 Anfertigung der Dissertation  
   unter Leitung von Prof. Simon Pot 
 am Departement für Pferde, Abteilung Ophthalmologie 
 der Vetsuisse-Fakultät  Universität Zürich 
 Direktor Prof. Anton Fürst 
  
Januar 2016 
Februar 2017 
 
Februar 2018  
– 
– 
 
– 
 
Januar 2017 
Januar 2018 
 
aktuell 
 
Tierärztin, Andreaspark-Tierärzte, Zürich, Schweiz 
Tierärztin Internship, Bessy’s Kleintierklinik, Watt-
Regensdorf, Schweiz 
Tierärztin, Marigin Zentrum für Tiermedizin, Feusisberg, 
Schweiz 
 
 
 	
